Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Evaluation of the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in Patients With Severe Hemophilia A.

NCT04864743 is registered in ClinicalTrials.gov with Hangzhou Gensciences Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04864743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04864743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Evaluation of the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in Patients With Severe Hemophilia A.
Lead sponsor
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2021
Completion date
October 17, 2021
Enrollment
13 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

severe hemophilia a